Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca-Nycomed antitrust charges dropped

Pharma companies cleared of delaying market entry of generic medicines

An investigation into whether AstraZeneca and Nycomed conspired to delay market entry of generic medicines into the EU has been dropped.

The European Commission (EC) called a halt to its antitrust investigation after finding no wrongdoing from either company.

The investigation had been prompted by an unannounced inspection of the companies' premises by the EC in November, 2010.

At the time the EC said it had "reason to believe that the companies concerned may have acted individually or jointly, notably to delay generic entry for a particular medicine".

"Such behaviour if established would have been contrary to EU antitrust rules that prohibit restrictive business practices and the abuse of a dominant market position," the Commission said.

The 2010 inspection followed an inquiry carried out by the EC between 2008 and 2009 into the industry, with a focus on possible delays of generic products to reach the market.

The inquiry found it often took as much as seven months after patent expiry before cheaper generic medicines became available.

The EC hasn't dropped its antitrust investigations altogether and other companies and continues to probe possible wrongdoing at Servier, Lundbeck, Cephalon, Teva, Johnson & Johnson and Novartis.

Last month, the EC dropped a misinformation investigation into whether Servier gave inaccurate details to the Commission's pharmaceuticals sector inquiry as part of the antitrust investigation.

The EC decided “significant” efforts would be needed to investigate Servier's defence and that the time would be better spent focused on the wider charges.

2nd March 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics